EVEREST-1 Trial Seeks to Bring HLA-A*02-directed CAR T to Pa

The upcoming phase 1/2 EVEREST-1 trial, where the novel CAR T-cell therapy A2B530 will be evaluated in patients with solid tumors, aims to push progress for one-and-done engineered therapies in this space.

Related Keywords

United States , New York , Dianem Simeone , , Pancreatic Cancer Center , Perlmutter Cancer Center , Tmodt Cell , News , Everest 1 Trial , Hlaa 02 Directed Cart Cell Therapy , Solid Tumors ,